Chemical modulators of store-operated calcium channels and their therapeutic applications

ABSTRACT

Methods of identification of inhibitors of calcium release-activated calcium (CRAC) channel and small molecule inhibitors of CRAC channel, including methods of their synthesis and pharmaceutical use, are disclosed.

CROSS-REFERENCES TO RELATED APPLICATION

This application claims the benefit of U.S. Patent Application No. 62/563,511, filed Sep. 26, 2017, the disclosure of which is incorporated herein by reference in its entirety.

STATEMENT OF GOVERNMENT LICENSE RIGHTS

This invention was made with Government support under Contract No. R01GM112003 awarded by the National Institutes of Health. The Government has certain rights in the invention.

STATEMENT REGARDING SEQUENCE LISTING

The sequence listing associated with this application is provided in text format in lieu of a paper copy and is hereby incorporated by reference into the specification. The name of the text file containing the sequence listing is TAMUS167344_SEQ_final_2018-09-20.txt. The text file is 2.88 KB; was created on Sep. 20, 2018; and is being submitted via EFS-Web with the filing of the specification.

BACKGROUND OF THE INVENTION

In cells, calcium (Ca²⁺) is an important secondary messenger, and the increase of calcium in cytoplasm is involved in various signaling pathways, further mediating a series of fundamental biological processes, such as contraction of skeletal muscles, release of neurotransmitters, metabolism of mitochondria, gene transcription, cell proliferation, differentiation, and apoptosis. Under normal physiological conditions, cells are exposed to high levels of calcium, and the extracellular concentration of calcium is about 1-2 mM. However, in the cytoplasm, the intracellular calcium concentration is 1,000-10,000 times lower, about 10⁻⁶-10⁻⁷ M. Additionally, in the intracellular calcium stores, mainly endoplasmic reticulum and sarcoplasmic reticulum, calcium concentration is about 10⁻⁵ M. This calcium gradient constitutes the foundation of calcium serving as a secondary messenger. Aberrant Ca²⁺ signaling is implicated in tumorigenesis and the pathogenesis of immunodeficiency, allergy, and autoimmune and inflammatory disorders. Targeting Ca²⁺ signaling pathway may hold therapeutic potential in the treatment of hematological malignancies and other solid cancers

Calcium signal is well controlled through various types of calcium channels in the cell membrane. In excitable cells, such as skeletal muscle and neuronal cells, calcium level is mainly regulated by voltage-gated calcium channels. However, in non-excitable cells, such as lymphocytes and most cancer cells, store-operated calcium (SOC) channel is the major calcium entry pathway from the extracellular space, in which depletion of calcium in intracellular stores can induce calcium influx through cell membrane. To date, several distinct store-operated channels have been reported, with the calcium release-activated calcium (CRAC) channel being the most well-characterized among them.

CRAC channel was first discovered in immune cells, where its function is well studied. Its two key components, the regulatory protein, STIM1 (the stromal interaction molecule 1) and the pore-forming subunit, Orai1 (also known as CRACM1) constitute the molecular basis of the CRAC current. STIM1, a single-transmembrane protein located in endoplasmic reticulum (ER) membrane, can sense the calcium concentration changes in ER. Orai1 has four transmembrane domains and exits as a multimer. After activation by STIM1, Orai1 forms a functional oligomer (most probably as a hexamer) to allow the calcium to pass through the channel. When antigens bind to T-cell and B-cell receptors or when antigen-antibody complex binds to Fc receptors on mast cells, natural killer cells, macrophages, and dendritic cells, phospholipase C (PLC) is activated and in turn hydrolyzes the phosphatidylinositol 4,5 bisphosphate PIP₂ to generate inositol-1,4,5-trisphosphate (IP3), which binds to the ER-resident IP3 receptor and triggers the release of Ca²⁺ from the ER lumen into cytoplasm. The decrease of free Ca²⁺ in ER stores is sensed by STIM1 via its ER-luminal EF-SAM domain that contains a Ca²⁺-binding EF-hand motif. Then, STIM1 forms oligomers and migrates toward ER-PM junctions (puncta), where it engages the ORAI1 Ca²⁺ channels and evokes Ca²⁺ influx. Finally, the resultant sustained elevation of cytosolic Ca²⁺ level activates the Ca²⁺/calmodulin-dependent phosphatase calcineurin and transcription factors, including nuclear factor of activated T cells (NFAT), which translocates from the cytoplasm to the nucleus and thereby regulates gene transcription during lymphocyte activation and differentiation. In addition to immune cells, CRAC channel is widely distributed in other various types of cells and tissues, including brain, lung, liver, kidney, spleen, thymus, lymph nodes, skeletal muscle, heart, bone, teeth, etc. Any effectors, such as ligand binding to some GPCRs receptors and tyrosine kinases receptors, that can stimulate the IP3 generation can also induce store-operated calcium current and further mediate the downstream signal pathway and regulated gene transcription.

Although both ORAI and STIM are widely expressed in different tissues, the clinical consequences of dysfunction of CRAC channel are primarily limited to the immune system. Thus, drug candidates that specifically target CRAC channels have a great potential to selectively suppress abnormal immune function and/or reduce the side effects of the existing immunosuppressant drugs, such as cyclosporin and tacrolimus. Additionally, abnormal CRAC channel activity, mainly due to augmented SOCE which resulted in cell calcium overload, was linked with other human diseases, such as myopathy, occlusive vascular diseases, cardiac hypertrophy, pancreatitis, and endothelial dysfunction. The role of CRAC channel in progression of cancers, such as in cancer cell growth, migration, invasion, and metastasis, is beginning to receive more attention. Dysregulated Ca²⁺ influx due to augmented STIM-ORAI signaling has been observed in many types of tumor cells, including breast, prostate, liver, lung, colon, skeletal muscle, cervical, nasopharyngeal, epidermoid, and glioma cancer cells, thereby making CRAC channel an attractive target for drug development.

A number of CRAC channel inhibitors have been developed, such as SKF-96365, 2-APB, BTP. However, presently, there are no viable clinical candidates because of the low selectivity and/or low activity exhibited by these compounds. Therefore, there is still an urgent need and high interest in developing novel CRAC channel inhibitors having high selectivity and potency.

SUMMARY OF THE INVENTION

In one aspect, provided herein is a CRAC channel inhibitor represented by Formula I:

or a pharmaceutically acceptable salt, solvate, or a hydrate thereof, wherein:

X is an optionally substituted C6-C10 aryl or an optionally substituted C5-C10 heteroaryl;

Y is an optionally substituted C1-C8 alkyl, an optionally substituted C6-C10 aryl-C1-C8 alkyl, an optionally substituted C5-C10 heteroaryl-C1-C8 alkyl, an optionally substituted C3-C10 heteroalkyl, an optionally substituted C3-C6 heterocyclyl, an optionally substituted C6-C10 aryl, or an optionally substituted C5-C10 heteroaryl; and

Z is an optionally substituted C6-C10 aryl or an optionally substituted C5-C10 heteroaryl.

In some embodiments of Formula I, X is an optionally substituted phenyl. In some embodiments, X is a phenyl substituted with one, two, or three groups selected from C1-C6 alkyl, carboxyl, alkoxycarbonyl, and amido group.

In some embodiments, the CRAC channel inhibitor has the structure of Formula II:

wherein

R¹ is H, an optionally substituted C1-C6 alkyl, COOH, COOR², CONH₂, or CONHR²;

R² is an optionally substituted C1-C6 alkyl;

Y is an optionally substituted C1-C8 alkyl, an optionally substituted C6-C10 aryl-C1-C8 alkyl, or an optionally substituted C5-C10 heteroaryl-C1-C8 alkyl; and

Z is an optionally substituted C6-C10 aryl or an optionally substituted C5-C10 heteroaryl.

In some embodiments of Formulae I or II, Y is an optionally substituted phenethyl.

In some embodiments of Formulae I or II, the CRAC channel inhibitor has the structure of Formula III:

wherein

R¹ is H, an optionally substituted C1-C6 alkyl, COOH, COOR², CONH₂, or CONHR²;

R² is an optionally substituted C1-C6 alkyl;

R⁴ is H or an optionally substituted C1-C6 alkyl;

R⁵ is H or an optionally substituted C1-C6 alkyl; and

Z is an optionally substituted C6-C10 aryl or an optionally substituted C5-C10 heteroaryl.

In some embodiments of Formulae I or II, Y is methyl, ethyl, propyl, n-butyl, tert-butyl, cyclopropyl, phenyl, benzyl, 4-methoxybenzyl, 3,4-dimethoxyphenyl, 4-sulfonamidophenethyl, or 5-methylbenzo[d][1,3]dioxolyl.

In some embodiments of Formulae I, II, or III, Z is phenyl, 4-halophenyl, 3-trifluoromethyl-phenyl, 2,5-dichlorophenyl, 3-chloro-4-methyl-phenyl, 2-methoxy-phenyl, 4-methoxycarbonyl-phenyl, benzo[d][1,3]dioxolyl, 3,5-dichlorophenyl, 3-methoxyphenyl, or 3-halophenyl.

In another aspect, provided herein is a method of treatment of a disease, disorder, or condition treatable by inhibiting CRAC channel in a subject, comprising administering to the subject in need thereof an amount of a CRAC channel inhibitor effective to inhibit CRAC channel, wherein the CRAC channel inhibitor is a compound of any one of Formulae I, II, or III.

In some embodiments, the condition treatable by inhibition of CRAC channel activity is an immune system disease, a hyperplastic disease, or cancer. In some embodiments, the condition is colon cancer, breast cancer, leukemia, or glioma. In some embodiments, the condition is an organ or a tissue transplant rejection.

In yet another aspect, provided herein is a pharmaceutical composition comprising a CRAC channel inhibitor represented by Formulae I, II, or III and a pharmaceutically acceptable carrier. In some embodiments, the composition further comprises one or more inactive components such as solvents, excipients, stabilizing agents, or diluents.

In yet another aspect, provided herein is a method of identifying an inhibitor of CRAC channel, the method comprising:

(a) generating on a computer a three-dimensional structure of human Orai1 protein of SEQ ID NO:1 by aligning the sequence of human Orai1 protein with the sequence of Orai1 protein from Drosophila melanogaster to generate a homology model of human Orai1;

(b) employing said three-dimensional model from step (a) to identify a potential inhibitor of CRAC;

(c) obtaining said potential inhibitor; and

(d) contacting said potential inhibitor with CRAC to determine the ability of said potential inhibitor to inhibit CRAC activity, whereby inhibition of CRAC activity identifies said inhibitor.

In some embodiments, the potential inhibitor forms hydrophobic or π-π interactions with Trp 377 and Trp 678 amino acids of SEQ ID NO:1 and salt bridge interactions with Arg 384 and Arg 986 amino acids of SEQ ID NO:1.

In some embodiments, the contacting of a potential inhibitor of CRAC with CRAC is an in vitro assay. In some embodiments, the in vitro assay is GFP-NFAT translocation assay.

In yet another aspect, provided herein is a method of preparing a compound of Formula I, wherein the method comprises:

(a) contacting a thiourea compound of Formula IV:

with a compound of Formula V:

in a suitable solvent thereby forming the compound of Formula I.

DESCRIPTION OF THE DRAWINGS

The foregoing aspects and many of the attendant advantages of this invention will become more readily appreciated as the same become better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings.

FIGS. 1A and 1B demonstrate the homology model of CRAC channel: top view (2A) and side view (2B).

FIG. 2 depicts the docking conformations (grey lines) of the compounds in the binding site of the CRAC homology model.

FIG. 3 summarizes the primary activity (NFAT nucleus-to-cytosol ratio) of Compounds 1-51 from the virtual screening.

FIG. 4 compares IC₅₀ curves of representative Compounds 3, 15, 21, and 41 from the virtual screening.

FIG. 5 demonstrates the inhibitory activity of Compound 41, a representative compound, on calcium influx.

FIG. 6 shows the proposed interactions of Compound 4, a representative compound, with CRAC channel.

FIG. 7 shows the structure of reported CRAC channel inhibitors that were used as the template to establish the pharmacophores used in the generation of the chemical structures of the compounds of the invention.

FIG. 8 is the schematic of the pharmacophore model of CRAC inhibitors showing Compound 41, a representative compound, bound to the CRAC channel.

FIGS. 9A-9F demonstrate that representative Compounds 87 (FIGS. 9A, 9C, and 9E) and 53 (FIGS. 9B, 9D, and 9F) significantly inhibit cytokine IL-2 expression in primary T cells, with the calculated IC₅₀ of 0.86±0.12 μM and 15.6±1.17 μM, respectively.

FIG. 10 shows that Compound 53 inhibits cytokine expression in Jurkat cells.

FIGS. 11A and 11B demonstrate the effect of Compound 87 on cell cycle in Jurkat cells: control (11A), Compound 87 (11B).

FIGS. 12A and 12B demonstrate the effect of Compound 87 on cell cycle in U87 cells: control (12A), Compound 87 (12B).

FIGS. 13A-13C show the inhibitory activity of representative Compounds 87, 53, 65, and 66 on the cell migration and invasion of MDA-MB-231 breast cancer cells: wound healing assay (13A), migration (13B), and invasion assay (13C).

FIGS. 14A and 14B demonstrate that Compound 53 has antitumor activity in the azoxymethane (AOM)-induced mouse colon cancer model by reducing the number of tumors formed compared to untreated control group and group treated with a known anti-cancer agent CsA.

DETAILED DESCRIPTION OF THE INVENTION

While the invention will be described in conjunction with the enumerated claims, it will be understood that they are not intended to limit the invention to those claims. On the contrary, the invention is intended to cover all alternatives, modifications, and equivalents, which may be included within the scope of the present invention as defined by the claims.

Definitions

As used herein, the term “alkyl” includes straight-chain, branched-chain, and cyclic monovalent hydrocarbyl radicals, and combinations thereof, which contain only C and H when they are unsubstituted. Examples include methyl, ethyl, isobutyl, cyclohexyl, cyclopentylethyl, 2-propenyl, 3-butynyl, and the like. The total number of carbon atoms in each such group is sometimes described herein, e.g., when the group can contain up to ten carbon atoms, it can be represented as 1-10C, C1-C10, C₁-C₁₀, C₁₋₁₀, or C1-10. The term “heteroalkyl,” as used herein, means the corresponding hydrocarbon wherein one or more chain carbon atoms have been replaced by a heteroatom. Exemplary heteroatoms include N, O, S, and P. When heteroatoms are allowed to replace carbon atoms, for example, in heteroalkyl groups, the numbers describing the group, though still written as e.g. C3-C10, represent the sum of the number of carbon atoms in the cycle or chain plus the number of such heteroatoms that are included as replacements for carbon atoms in the cycle or chain being described.

Alkyl groups can be optionally substituted to the extent that such substitution makes sense chemically. Typical substituents include, but are not limited to, halogens (F, Cl, Br, I), ═O, ═NCN, ═NOR, ═NR, OR, NR₂, SR, SO₂R, SO₂NR₂, NRSO₂R, NRCONR₂, NRC(O)OR, NRC(O)R, CN, C(O)OR, C(O)NR₂, OC(O)R, C(O)R, and NO₂, wherein each R is independently H, C1-C8 alkyl, C2-C8 heteroalkyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, or C5-C10 heteroaryl, and each R is optionally substituted with halogens (F, Cl, Br, I), ═O, ═NCN, ═NOR′, ═NR′, OR′, NR′₂, SR′, SO₂R′, SO₂NR′₂, NR′SO₂R′, NR′CONR′₂, NR′C(O)OR′, NR′C(O)R′, CN, C(O)OR′, C(O)NR′₂, OC(O)R′, C(O)R′, and NO₂, wherein each R′ is independently H, C1-C8 alkyl, C2-C8 heteroalkyl, C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl or C5-C10 heteroaryl. Alkyl groups can also be substituted by C1-C8 acyl, C2-C8 heteroacyl, C6-C10 aryl, or C5-C10 heteroaryl, each of which can be substituted by the substituents that are appropriate for the particular group.

“Aromatic” or “aryl” substituent or moiety refers to a monocyclic or fused bicyclic moiety having the well-known characteristics of aromaticity; examples of aryls include phenyl and naphthyl. Similarly, “heteroaromatic” and “heteroaryl” refer to such monocyclic or fused bicyclic ring systems which contain as ring members one or more heteroatoms. Suitable heteroatoms include N, O, and S, inclusion of which permits aromaticity in 5-membered rings as well as 6-membered rings. Typical heteroaromatic systems include monocyclic C5-C6 aromatic groups such as pyridyl, pyrimidyl, pyrazinyl, thienyl, furanyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, and imidazolyl, and fused bicyclic moieties formed by fusing one of these monocyclic groups with a phenyl ring or with any of the heteroaromatic monocyclic groups to form a C8-C10 bicyclic group such as indolyl, benzimidazolyl, indazolyl, benzotriazolyl, isoquinolyl, quinolyl, benzothiazolyl, benzofuranyl, pyrazolopyridyl, quinazolinyl, quinoxalinyl, cinnolinyl, and the like. Any monocyclic or fused ring bicyclic system which has the characteristics of aromaticity in terms of electron distribution throughout the ring system is included in this definition. It also includes bicyclic groups where at least the ring which is directly attached to the remainder of the molecule has the characteristics of aromaticity. Typically, the ring systems contain 5-14 ring member atoms. Typically, monocyclic heteroaryls contain 5-6 ring members, and bicyclic heteroaryls contain 8-10 ring members. When heteroatoms are allowed to replace carbon atoms in heteroaryl groups, the numbers describing the group, though still written as, e.g. C5-C10, represent the sum of the number of carbon atoms in the cycle plus the number of such heteroatoms that are included as replacements for carbon atoms in the cycle being described. For example, a pyridyl group can be referred to as a C6 heteroaryl.

Aryl and heteroaryl moieties can be substituted with a variety of substituents including C1-C8 alkyl, C5-C12 aryl, C1-C8 acyl, and heteroforms of these, each of which can itself be further substituted; other substituents for aryl and heteroaryl moieties include halogens (F, Cl, Br, I), OR, NR₂, SR, SO₂R, SO₂NR₂, NRSO₂R, NRCONR₂, NRC(O)OR, NRC(O)R, CN, C(O)OR, C(O)NR₂, OC(O)R, C(O)R, and NO₂, wherein each R is independently H, C1-C8 alkyl, C2-C8 heteroalkyl, C6-C10 aryl, C5-C10 heteroaryl, C6-C10 aryl-C1-C5 alkyl, or C5-C10 heteroaryl-C1-C5 alkyl, and each R is optionally substituted as described above for alkyl groups. The substituent groups on an aryl or heteroaryl group can be further substituted with the groups described herein as suitable for each type of such substituents or for each component of the substituent. Thus, for example, an arylalkyl substituent can be substituted on the aryl portion with substituents described herein as typical for aryl groups, and it can be further substituted on the alkyl portion with substituents described herein as typical or suitable for alkyl groups.

As used herein, the term “arylalkyl” refers to an alkyl substituted with an aryl. Arylalkyls are represented by the number of carbon atoms in each alkyl and aryl; for example, a C6 aryl-C2 alkyl refers to a C2 alkyl substituted with a C6 aryl. Non-limiting examples of arylalkyls are benzyl (a C6 aryl-C1 alkyl) and phenethyl (a C6 aryl-C2 alkyl). Similarly, the term “heteroarylalkyl” refers to an alkyl substituted with a heteroaryl. Heteroarylalkyls are represented by the number of carbon atoms in each alkyl and heteroaryl; for example, a C6 heteroaryl-C2 alkyl refers to a C2 alkyl, e.g., ethyl, substituted with a C6 heteroaryl, e.g., pyridyl.

“Optionally substituted,” as used herein, indicates that the particular group being described can have one or more hydrogen substituents replaced by a non-hydrogen substituent. In some optionally substituted groups or moieties, all hydrogen substituents are replaced by a non-hydrogen substituent (e.g., a polyfluorinated alkyl such as trifluoromethyl). If not otherwise specified, the total number of such substituents that can be present is equal to the number of H atoms present on the unsubstituted form of the group being described. Where an optional substituent is attached via a double bond, such as a carbonyl oxygen or oxo (═O), the group takes up two available valences, so the total number of substituents that may be included is reduced according to the number of available valences.

As used herein, the term “immune system diseases” refers to a series of disorders of the immune system, including immunodeficiency disorders, overactive immune response (allergy), and autoimmune disorders (e.g., disorders in which the immune system attacks normal and healthy tissues). The immune diseases that can be treated with the compounds of the invention are preferably the conditions induced by the overactive or abnormal immune recognition.

A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, for example, reduced levels of CRAC channel activity. A therapeutically effective amount of a compound can vary according to factors such as the disease state, age, sex, and weight of the subject, and the ability of the compound to elicit a desired response in the subject. An individual therapeutically effective amount can be determined according to the methods known in the art. Dosage regimens can be adjusted to provide the optimum therapeutic response. A therapeutically effective amount is also one in which any toxic or detrimental effects of the compound are outweighed by the therapeutically beneficial effects. A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, such as inhibition of CRAC channel.

As used herein, the term “treat”, “treating”, and “treatment” refer to administering a compound of the invention or a pharmaceutical composition comprising a compound of the invention to a patient thereby generating a therapeutic effect, such as eliminating or alleviating one or more existing symptoms of a disease, preventing any additional symptoms, and/or preventing further progression of the disease. As used herein, the term “disease, disorder, or condition treatable by inhibiting CRAC channel” refers to a disease, disorder, or condition in which CRAC channel is involved in the pathway related to for the disease, disorder, or condition, and that inhibiting CRAC channel results in the treatment or prevention of the disease, disorder, or condition.

As used herein, the term “transplantation” refers to removal of organs, bone marrow, stem cell, or other tissues from one subject and insertion into another subject. After transplantation, the functionality and viability of the transplanted organs, bone marrow, stem cell, and/or tissues in the new host can be maintained through the use of an immunosuppressant.

Compound Virtual Screening

Compared with the classical drug discovery methods, computer-aided drug discovery is a convenient and low-cost way to find a lead compound with a novel chemical scaffold. To date, few literature reports describing the use of this method to discover CRAC channel inhibitors have been published. In this invention, based on the crystal structure of Orai1 from Drosophila melanogaster, the inventors have built a virtual screening method to discover novel CRAC channel inhibitors. Specifically, first the human Orai1 amino acid sequence was obtained from Uniprot database (Uniprot ID: Q96D31). Then, the alignment of the amino acid sequence between human Orai1 protein and Drosophila melanogaster Orai1 protein was conducted using the Cobalt method. Then, according to the alignment results, Modeler 9.11 software was used to generate the homology model of human Orai1. Then, the rough model was solvated by using the TIP3P water model, subjected to 500-steps of molecular mechanics minimization and molecular dynamics simulations at 300 K for 1.0 ns using the SANDER module in AMBER 8 program to obtain a refined model, as shown in FIG. 2. Then, using this CRAC homology model and DOCK 6 software, a virtual screening of the SPECS database containing about 300,000 compounds was conducted. About 51 compounds were identified for biological evaluation. The structures of the compounds are shown in Table 1, and the docking results are shown in FIG. 3.

TABLE 1 Structures of some representative hits from the virtual screening experiments Compound Number Structure of the compounds IC₅₀ Value 01

>200 02

>200 03

143.7 04

>200 05

>200 06

>200 07

>200 08

>200 09

>200 10

>200 11

>200 12

>200 13

>200 14

>200 15

173.6 16

>200 17

>200 18

>200 19

>200 20

>200 21

60.3 (agonist) 22

>200 23

>200 24

>200 25

>200 26

>200 27

>200 28

>200 29

>200 30

>200 31

>200 32

>200 33

>200 34

>200 35

>200 36

>200 37

>200 38

>200 39

>200 40

>200 41

278.83 42

>200 43

>200 44

>200 45

>200 46

>200 47

>200 48

>200 49

>200 50

>200 51

>200

Inhibitory Activity Assay on CRAC Channel

It is known that thapsigargin (TG) can induce the CRAC channel to open resulting in the calcium influx. The elevation of calcium in cytoplasm can activate the Ca²⁺-calcineurin-NFAT pathway followed by NFAT translocation from the cytoplasm to the nucleus to regulate gene transcription. Therefore, the inventors built a GFP-NFAT translocation-based high-content screening method to evaluate the activity of compounds on CRAC channel. Briefly, a HeLa cell line stably expressing GFP-NFAT was established and used, and the images after chemical stimulation in the presence of TG were acquired using an IN Cell Analyzer 6000 confocal laser imaging system, and then the GFP fluorescent intensity ratio between cytoplasm and nucleus was analyzed to reflect the inhibitory activity of compound on CRAC channel.

Briefly, GFP-NFAT stable cells were cultured in Dulbecco's modified eagle's medium (DMEM) supplemented with 10% FBS in 5% carbon dioxide at 37° C. When it reached 90% confluency, a cell suspension with a concentration of 8000/mL was prepared, and an amount of 2000 cells per well (25 μL/well) was seeded in 384 well plate, putting it at the room temperature for 1 h to make sure the cells distribute evenly, then the cells were incubated overnight. First, primary screening of the selected compounds was conducted. A series of compound solutions with a concentration of 200 μM in MEDM medium were prepared in a 96 well plate and then added to a 384 well plate using a Beckman Coulter automatic drug adding system, in 4 duplicates, and incubated for 30 min at 37° C. SKF was selected as the positive control. Then, 1 μM TG and 1 mM Ca²⁺ were added to 384-well plate using Beckman Coulter automatic drug adding system and incubated for 20 min. Subsequently, 384 well plate was gently washed with PBS twice, and the cells were fixed with 4% PFA (25 μl per well) for 10˜15 mins at room temperature, then washed with PBS gently, added 0.5% Triton X-100 (25 μL per well), and incubated for 5 mins aFt room temperature, stained with DAPI (1 μg/mL) for 5˜10 mins at room temperature, washed with PBS and added 30 μL PBS per well to image on confocal laser imaging system (objective lens: 10×, FITC and UV). Using Pipeline Plot software (NAFT translocation protocol), the intensity of green fluorescence was analyzed in nucleus and cytosol, calculate the ratio of nucleus: cytosol, normalize TG stimulate NFAT translocation as 1 and no TG adding as 0. Finally, the data was analyzed using GraphPad Prism 5 software. The compounds which showed activity on CRAC channel were further evaluated and the IC₅₀ value was calculated using the same method described above.

The inhibitor activity on CRAC of these 51 compounds screened out from the small molecule library were evaluated using the method describe above. The result showed that Compounds 03, 15, and 41 demonstrated good activity (FIG. 3). Then, the IC₅₀ of these three compounds were calculated, and as shown in FIG. 4, the IC₅₀ value was about 100 μM. It was noted that compounds Compound 03 and Compound 41 have a similar chemical structure that contain a general substructure. Therefore, the compounds with the similar chemical structure may have inhibitory activity on calcium influx CRAC channel. In addition, Compound 41 also showed obvious inhibitory activity on calcium influx, as illustrated in FIG. 5. Therefore, the Compound 41 was selected as the lead compound to optimize the structure so as to improve the activity.

Optimization of Compound 41

In order to understand the interaction between Compound 41 and CRAC channel, the structure of Compound 41 was re-docked into the active site, and the interactions were optimized by molecular mechanics and molecular dynamics. After refinements, it was found that the interaction between Compound 41 and CRAC channel seems to be mainly dependent on strong hydrophobic and/or π-π interactions with Trp 377 and Trp 678, as well as salt bridge interactions with Arg 384 and Arg 986 (as shown in FIG. 7).

In addition, in order to aid the lead compound optimization, a working pharmacophore model was developed based on the structure of reported CRAC channel inhibitors, which are shown in FIG. 7, using the Hipop algorithm implemented in the Discovery Studio package. Briefly, the initial working pharmacophore model built consisted of three common features as critical fragments for activities: one hydrogen binding acceptor and two hydrophobic groups (as shown in FIG. 8). Such results are consistent with the homology model as well. This model in conjunction with the interaction model was used to guide the optimization of the lead compounds.

Thus, in an aspect, provided herein is a method of identifying an inhibitor of CRAC channel, the method comprising:

(a) generating on a computer a three-dimensional structure of human Orai1 protein of SEQ ID NO:1 by aligning the sequence of human Orai1 protein with the sequence of Orai1 protein from Drosophila melanogaster to generate a homology model of human Orai1;

(b) employing said three-dimensional model from step (a) to identify a potential inhibitor of CRAC;

(c) obtaining said potential inhibitor; and

(d) contacting said potential inhibitor with CRAC to determine the ability of said potential inhibitor to inhibit CRAC activity, whereby inhibition of CRAC activity identifies said inhibitor.

In some embodiments, the potential inhibitor forms hydrophobic or π-π interactions with Trp 377 and Trp 678 amino acids of SEQ ID NO:1 and salt bridge interactions with Arg 384 and Arg 986 amino acids of SEQ ID NO:1.

In some embodiments, the contacting of a potential inhibitor of CRAC with CRAC is an in vitro assay. In some embodiments, the in vitro assay is GFP-NFAT translocation assay.

In some embodiments, in the optimization procedure described above, the 3-mercapto-pyrrolidine-2,5-dione scaffold of Formula I was fixed, and the X, Y, and Z groups in the structure were varied. This is different from the classical SAR optimization method, in which a series of the lead compound analogs is synthesized via complex and time-consuming synthetic procedures. The inventors searched for analogues of Compound 41 in the existing small molecule libraries, including Zinc, Specs, and other libraries. In addition, PubChem searching pool was used for identification of analogous structures. Some selected compounds (Compounds 52-74) are shown in Table 2.

TABLE 2 Exemplary structures of the compounds optimized from the lead Compound 41 and their inhibitory activity on CRAC channel. Compound IC₅₀ of the Number Compound Structure compounds 52

>200 53

13.0 54

>200 55

>200 56

>200 57

>200 58

>200 59

>200 60

>200 61

>200 62

11.28 63

74.38 64

24.89 65

30.57 66

10.47 67

>200 68

>200 69

107.9 70

>200 71

>200 72

>200 73

>200 74

>200 75

>200 76

>200 77

>200 78

>200 79

11.67 80

>200 81

>200 82

22.35 83

>200 84

>200 85

>200 86

6.34 87

0.95 88

>200 89

>200 90

>200 91

>200 92

>200 93

>200 94

>200 95

>200 96

10.89 97

>200 98

21.21 99

18.17 100

14.82 101

11.21 102

9.20 103

15.84 104

>200 105

>200 106

5.01 107

>200 108

>200 109

>200 110

>200 111

1.60 112

0.20 113

5.83 114

>200 115

5.84 116

>200 117

>200 118

>200 119

>200 120

>200

In some embodiments, the CRAC channel inhibitors described herein have the general structure of Formula I:

wherein

X is an optionally substituted alkyl, an optionally substituted heterocyclyl, an optionally substituted aryl, or an optionally substituted heteroaryl;

Y is an optionally substituted alkyl, an optionally substituted heterocyclyl, an optionally substituted aryl, or an optionally substituted heteroaryl; and

Z is an optionally substituted alkyl, an optionally substituted heterocyclyl, an optionally substituted aryl, or an optionally substituted heteroaryl.

In some embodiments of Formula I, X is an optionally substituted C6-C10 aryl or an optionally substituted C5-C10 heteroaryl;

Y is an optionally substituted C1-C8 alkyl, an optionally substituted C6-C10 aryl-C1-C8 alkyl, an optionally substituted C5-C10 heteroaryl-C1-C8 alkyl, an optionally substituted C3-C10 heteroalkyl, an optionally substituted C3-C6 heterocyclyl, an optionally substituted C6-C10 aryl, or an optionally substituted C5-C10 heteroaryl; and

Z is an optionally substituted C6-C10 aryl or an optionally substituted C5-C10 heteroaryl.

In some embodiments of Formula I, X is an optionally substituted phenyl. In some embodiments, X is a phenyl substituted with one or more groups selected from halogen, C1-C6 alkyl, carboxyl, alkoxycarbonyl, amido, or a combination thereof. In some embodiments, X is an unsubstituted phenyl.

In some embodiments of Formula I, X is an optionally substituted C5 or C6 heteroaryl, such as thiophenyl, pyridyl, or pyrimidinyl. In some embodiments of Formula I, X is a C5 or C6 hereroaryl substituted with one or more groups selected from halogen, C1-C6 alkyl, carboxyl, alkoxycarbonyl, amido, or a combination thereof. In some embodiments of Formula I, X is a 4-substituted phenyl, wherein the substituent is an optionally substituted C1-C6 alkyl, COOH, COOR², CONH², or CONHR², wherein R² is an optionally substituted C1-C6 alkyl

In some embodiments, the CRAC channel inhibitors described herein have the structure of Formula II:

wherein

R¹ is H, an optionally substituted C1-C6 alkyl, COOH, COOR², CONH₂, or CONHR²;

R² is an optionally substituted C1-C6 alkyl;

Y is an optionally substituted C1-C8 alkyl, an optionally substituted C6-C10 aryl-C1-C8 alkyl, or an optionally substituted C5-C10 heteroaryl-C1-C8 alkyl; and

Z is an optionally substituted C6-C10 aryl or an optionally substituted C5-C10 heteroaryl.

In some embodiments of Formulae I or II, Y is (CH₂)_(n)Ar, wherein n is an integer between 1 and 5 and Ar is an optionally substituted C6-C10 aryl or C5-C10 heteroaryl. In some embodiments, Y is an optionally substituted phenethyl. In some embodiments, Y is a phenethyl substituted with 1 or 2 groups selected from halogen, SO₂NHR³, CO₂R³, or CONHR³, wherein R³ is H or C1-C6 alkyl.

In some embodiments of Formulae I or II, Y is methyl, ethyl, propyl, n-butyl, tert-butyl, cyclopropyl, phenyl, benzyl, 4-methoxybenzyl, 3,4-dimethoxyphenyl, 4-sulfonamidophenethyl, or 5-methylbenzo[d][1,3]dioxolyl.

In some embodiments, the CRAC channel inhibitors described herein have the structure of Formula III:

wherein

R¹ is H, an optionally substituted C1-C6 alkyl, COOH, COOR², CONH₂, or CONHR²;

R² is an optionally substituted C1-C6 alkyl;

R⁴ is H or an optionally substituted C1-C6 alkyl;

R⁵ is H or an optionally substituted C1-C6 alkyl; and

Z is an optionally substituted C6-C10 aryl, or an optionally substituted C2-C10 heteroaryl.

In some embodiments of Formulae I, II, or III, Z is phenyl, 4-halophenyl, 3-trifluoromethyl-phenyl, 2,5-dichlorophenyl, 3-chloro-4-methyl-phenyl, 2-methoxyphenyl, 4-methoxycarbonyl-phenyl, benzo[d][1,3]dioxolyl, 3,5-dichlorophenyl, 3-methoxyphenyl, or 3-halophenyl.

In some embodiments of Formula III, R⁴ and R⁵ are H.

In some embodiments, the condition treatable by inhibition of CRAC channel activity is an immune system disease, a hyperplastic disease, or cancer. In some embodiments, the condition is colon cancer, breast cancer, leukemia, or glioma. In some embodiments, the condition is an organ or a tissue transplant rejection.

The activity CRAC channel inhibitory activity of the compounds of Formulae I, II, or III disclosed herein can be determined in vitro, for example, using a GFP-NFAT translocation assay method as described below.

Using the GFP-NFAT translocation assay method, the inhibitory activity of the selected compounds at 200 μM concentration was evaluated. As demonstrated in Table 2, several compounds showed good inhibition of CRAC channel, for example, Compounds 53, 62, 65, and 66. Then, IC₅₀ values were calculated, with Compound 53 having the lowest IC₅₀ at 8.14 μM. This IC₅₀ value demonstrates an order of magnitude, e.g., about tenfold, improvement compared to the IC₅₀ of the lead Compound 41 (shown in Table 1). Based on the result, a series of Compound 53 analogues was designed and synthesized de novo. The structures of several exemplary synthesized compounds (Compounds 75-104) are shown in Table 2.

The compounds described herein showed good inhibitory activity on CRAC channel. Analyzing the structure and activity relationship, it was found that group Y in Formula I is important for activity. In some embodiments, retaining the 4-sulfonamide-phenethyl group resulted in the preservation of the compound activity. In certain embodiments, if 3-substituted 2,5-pyrrolidinedione core structure was disrupted, the inhibitory activity disappeared.

Pharmaceutical Application of Compounds

The association of dysfunction of CRAC channel activity with various diseases such as cancer and autoimmune diseases has been validated in the literature. Therefore, in the following experiments, the activity of these compounds was evaluated in different models, and it was found that exemplary compounds of the disclosure, Compounds 53 and 87, significantly inhibit cytokine IL-2 expression in primary T cells, with the calculated IC₅₀ of 15.6±1.17 μM and 0.86±0.12 μM respectively (as shown in FIGS. 9A-9F). In addition, the antitumor effect of these compounds was also tested in different cancer cell models, including a leukemia cell line (Jurkat cells), a breast cancer cell line (MDA-MB-231), and a glioma cell line (U87). Compound 87 can induce cell cycle arrest at G0 stage in Jurkat (FIG. 11B) and U87 cells (FIG. 12B) compared to their respective controls (FIGS. 11A and 12A). Compound 53 can also inhibit IL-2 and IFNγ expression in Jurkat cell (FIG. 10). In a wound healing assay, representative compounds of the disclosure, Compounds 53, 65, 66, and 87, can greatly inhibit MDA-MB-231 cell migration (as shown in FIGS. 13A and 13B). Meanwhile, representative compounds of the disclosure, Compounds 53 and 87 can greatly inhibit the MDA-MB-231 cell invasion (FIG. 13C). In the azoxymethane-induced mouse colon cancer model, representative compound of the disclosure, Compound 53, can greatly decrease the number of the formed tumors in the colon, and the activity is also better than the positive control drug CsA (as demonstrated in FIGS. 14A and 14B).

These results indicate that blocking CRAC channel function, e.g., by compounds of Formulae I-III, can produce a therapeutic effect. For example, the compounds in the invention can be particularly useful to treat one or more of the following diseases: 1) immune system diseases, 2) hyperplastic diseases, and 3) cancer. Additionally, in some embodiments, the compounds can be used to suppress or prevent transplant immune rejection reaction.

Thus, in another aspect, disclosed herein is a method of treatment of a condition associated with an abnormal CRAC channel activity in a subject in need thereof, comprising administering to the subject an amount of a CRAC channel inhibitory agent in the amount effective to inhibit CRAC channel, wherein the CRAC channel inhibitory agent is a compound of Formula I, Formula II, or Formula III. In some embodiments, the CRAC channel inhibitor is Compound 41, 53, 62, 63, 64, 65, 66, 69, 79, 86, 87, 98, 99, 100, 101, 102, 103, 106, 111, 112, or 113. In some embodiments, the CRAC channel inhibitor is Compound 53 or 87.

Specifically, the compounds disclosed herein, e.g., compounds of Formulae I, II, or III, can be used to treat the immune system diseases. In some embodiments, the immune system diseases include but are not limited to autoimmune diseases and the related inflammation, such as systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, dermatomyositis, multiple sclerosis, autoimmune hemolyticanemia, thyroiditis, ulcerative colitis, eczema, psoriasis, vasculitis, pancreatitis, myasthenia gravis, glomerulonephritis, allergy, allergic inflammation (allergic rhinitis), asthma, uveitis, neurogenic inflammation, and diabetes type 1.

In particular embodiments, the compounds of the invention can be applied to treat hyperplastic diseases, including but not limited to cardiac hypertrophy, benign prostatic hyperplasia, familial adenomatous polyposis, neurofibromatosis, psoriasis, hypertrophic scar, myelodysplastic syndromes, cystic fibrosis, and atherosclerosis hamper.

In other embodiments, the compounds of the invention can be used to treat various types of cancers, including but not limited to leukemia, lymphoma, breast cancer, prostate cancer, liver cancer, lung cancer, colon cancer, skeletal muscle, cervical cancer, nasopharyngeal cancer, epidermoid cancer, esophageal cancer, pancreatic cancer, thyroid cancer, rhabdomyosarcoma, glioma, osteosarcoma, neuroblastoma, astrocytoma, and schwannoma.

In certain embodiments, the compounds of Formulae I, II, or III can suppress the immune rejection in transplant, such as organ, marrow, stem cell, or other tissues or cell transplant.

In other embodiments, the compounds of the Formulae I, II, or III can be used as their pharmaceutically acceptable salts, solvates, or hydrates.

Preparation of pharmaceutical salts is well known to those persons skilled in the art. When there is an acidic group present in the structure of a pharmaceutically active compound, such as the compounds of the present invention, pharmaceutically acceptable salts can be prepared by contacting the compound with a nontoxic inorganic base, including potassium, sodium, calcium, ammonium, lithium, ferric, copper, and magnesium hydroxides. In some embodiments, pharmaceutically acceptable salts can be prepared by contacting the compound with a nontoxic organic base, including but not limited to arginine, betaine, histidine, N-methyl glucamine, lysine, L-glucamine and others. In some embodiments, when a basic group is present in the structure of a pharmaceutically active compound, such as the compounds of the present invention, pharmaceutically acceptable salts can be prepared by contacting the compound with a nontoxic acid, for example, hydrochloric, hydrobromic, sulfuric, acetic, phosphoric, tartaric, citric, fumatric, nitric, gluconic, malic, glutamic, and succinic acids.

Pharmaceutical solvates or hydrates of the compounds of the present invention can be formed by freeze-drying the solutions of the compounds in water or any other suitable solvent, e.g., ethanol, methanol, DMSO, acetic acid, isopropanol, ethyl acetate, ethanolamine. The general methods of preparation of solvates and hydrates method are well known to persons skilled in the art.

In certain embodiments, the compounds of the invention, or their pharmaceutical salts, solvates, or hydrates can be administered in their pure form. However, more typically, it is desirable to administer a pharmaceutical agent in the form of a pharmaceutical composition, wherein the composition comprises the active ingredient and one or more pharmaceutically acceptable carriers or excipients. In some embodiments, inclusion of such carriers or excipients does not affect the activity of compounds in the invention. Specifically, the pharmaceutical carriers include but are not be limited to water, saline, glucose, buffer, glycerol, ethanol, olive oil, peanut oil, and other ingredients. In some embodiments, pharmaceutical excipients include but not to be limited to binders (e.g., dextrin, hydroxypropyl methylcellulose, polyvinyl pyrrolidone), fillers (e.g., lactose, starch, microcrystalline cellulose), disintegrating agents (e.g., croscarmellose sodium), lubricants (e.g., magnesium stearate), glidants (e.g., colloidal silicon dioxide), surfactants (e.g., tween), solubilizers (e.g., PEG), antiseptics, flavoring agents, etc. In some instances, the carriers and/or excipients are compounds or ingredients designated as GRAS by the FDA. Formulation of active pharmaceutical ingredients is well known to the persons skilled in the art.

Suitable pharmaceutical compositions include but not limited to a tablet, a pill, a granule, a capsule, a power, a syrup, an emulsion, a topical cream, a suppository, a suspension, an ointment, an inhalant, a patch, a gel, and an injectable. In some embodiments, the compositions are sustained release formulas. A person skilled in the art is able to select the appropriate type of the pharmaceutical composition and/or formulation depending on the administration route.

The modes of administration include but are not be limited to oral, intravenous, subcutaneous, intramuscular, rectal, and parenteral. The amounts of the active ingredients that can be combined with pharmaceutical carriers or excipients to form single doses vary depending on the host to be treated and the mode of administration. In some instances, the suggested dose can range from about 0.001 mg/kg to about 100 mg/kg each and 1-3 times intake daily. In some embodiments, the active ingredient, e.g., one of the presently described compounds, can also be administered in combination with one or more other pharmaceutical agents to increase the efficacy of the treatment.

EXAMPLES

As can be appreciated from the disclosure above, the present invention has a wide variety of applications. The invention is further illustrated by the following examples, which are only illustrative and are not intended to limit the definition and scope of the invention in any way.

Example 1 Synthesis of Representative Compounds (1) Synthesis of (Z)-methyl 4-(3-((N-methyl-N′-phenylcarbamimidoyl)thio)-2,5-dioxopyrrolidin-1-yl)benzoate

Synthesis of 1-methyl-3-phenylthiourea

To a solution of methylamine hydrochloride (1.35 g) in THF (50 mL), triethylamine (3.06 mL) and phenyl isothiocyanate (2.56 mL) were added respectively, and the mixture was stirred for 5 hrs at room temperature, and then concentrated. The concentrate was purified by column chromatography on silica gel to afford white solid (3.20 g, 96%), m.p. 90-92° C. ¹H NMR (400 MHz, DMSO): δ (ppm) 9.45 (1H, s), 7.67 (1H, s), 7.32 (4H, m), 7.11 (1H, m), 2.91 (3H, d, J=4.4 Hz); MS (ES) [M+H]⁺ 167.2.

Synthesis of (Z)-4-((4-(methoxycarbonyl)phenyl)amino)-4-oxobut-2-enoic Acid

A mixture of maleic anhydride (1.96 g) and methyl 4-aminobenzoate (3.02 g) in THF (60 mL) was stirred at room temperature for 3 hrs, and the precipitate was filtered off, washed with ethyl acetate and dried to give light yellow powder (4.73 g, 95%), m.p. 190-192° C. ¹H NMR (400 MHz, DMSO) δ (ppm) 10.63 (1H, s), 7.92 (2H, d, J=8.70 Hz), 7.75 (2H, d, J=8.70 Hz), 6.45 (1H, d, J=12.00 Hz), 6.33 (1H, d, J=12.00 Hz), 4.27 (2H, q), 1.29 (3H, t); MS (ES) [M+H]⁺ 250.3.

Synthesis of methyl 4-(3-bromo-2,5-dioxopyrrolidin-1-yl)benzoate

Acetyl bromide (0.34 mL) was added to the suspension of (Z)-4-((4-(methoxycarbonyl)phenyl)amino)-4-oxobut-2-enoic acid (996 mg) in ethyl acetate. The mixture was stirred at 30° C. for 2 hrs, and then heated to reflux for 10 hrs. The solvent was concentrated and the residue was purified by column chromatography on silica gel to afford white solid (690 mg, 56%), m.p. 154-156° C. ¹H NMR (400 MHz, DMSO): δ (ppm) 8.12 (2H, d, J=8.0 Hz), 7.51 (2H, d, J=8.0 Hz), 5.22-5.19 (1H, m), 3.89 (3H, s), 3.66-3.59 (1H, m), 3.21-3.16 (1H, m); MS (ES) [M+H]⁺ 167.2.

Synthesis of (Z)-methyl 4-(3-((N-methyl-N′-phenylcarbamimidoyl)thio)-2,5-dioxopyrrolidin-1-yl)benzoate

The mixture of 1-methyl-3-phenylthiourea (83 mg) and methyl 4-(3-bromo-2,5-dioxopyrrolidin-1-yl)benzoate (156 mg) in THF (3 mL) was stirred at reflux for 6 hrs, and the solvent was concentrated. The residue was purified by column chromatography on silica gel to afford white solid (120 mg, 61%), m.p. 191-192° C. 1H NMR (400 MHz, DMSO): δ (ppm) 7.92 (2H, d, J=8.0 Hz), 7.78 (2H, d, J=8.0 Hz), 7.62 (2H, d, J=8.0 Hz), 7.46 (2H, d, J=8.0 Hz), 7.36-7.30 (2H, m), 7.10 (1H, t, J=8.0 Hz), 6.81 (2H, d, J=8.0 Hz), 4.56-4.53 (1H, m), 4.04-4.01 (2H, m), 3.81 (3H, s), 3.30-3.25 (1H, m), 3.06 (1H, t, J=8.0 Hz), 2.96-2.89 (1H, m); MS (ES) [M+H]+ 398.2.

(2) Synthesis of (Z)-methyl 4-(3-((N′-(2-methoxyphenyl)-N-methylcar-bamimidoyl)thio)-2,5-dioxopyrrolidin-1-yl)benzoate

Synthesis of 4-(2-(3-(4-methoxyphenyl)thioureido)ethyl)benzenesulfonamide

To a mixture of 1,1′-thiocarbonyl diimidazole (320 mg) and p-anisidine (180 mg) in DMF (3 mL), 4-(2-aminoethyl)benzenesulfonamide (330 mg) was added, and the mixture was stirred at room temperature for 5 hrs. Then water was added and the mixture was extracted with EtOAc. The organic layers were combined, washed with water and brine respectively, dried over Na₂SO₄, filtered, and concentrated in vacuo to give white solid powder (510 mg, 93%), m.p. 160-162° C. ¹H NMR (400 MHz, DMSO): δ (ppm) 9.61 (s, 1H), 7.86 (s, 1H), 7.76 (d, J=8.0 Hz, 2H), 7.62 (d, J=8.0 Hz, 2H), 7.43 (d, J=8.0 Hz, 2H), 7.31 (s, 2H), 7.19 (d, J=8.0 Hz, 2H), 3.93 (s, 3H), 3.72-3.69 (m, 2H), 2.94 (t, J=7.4 Hz, 2H); MS (ES) [M+H]⁺ 365.3.

Synthesis of (E)-methyl 4-(3-((N′-(4-methoxyphenyl)-N-(4-sulfamoylphenethyl)-carbamimidoyl)thio)-2,5-dioxopyrrolidin-1-yl)benzoate

A mixture of 4-(2-(3-(4-methoxyphenyl)thioureido)ethyl)benzenesulfonamide (183 mg) and methyl 4-(3-bromo-2,5-dioxopyrrolidin-1-yl)benzoate (156 mg) in THF (3 mL) was stirred at reflux for 6 hrs, and the solvent was concentrated. The residue was purified by column chromatography on silica gel to afford white solid (197 mg, 66%), m.p. 176-178° C. ¹H NMR (400 MHz, DMSO): δ (ppm) 10.49 (1H, s), 7.92 (2H, d, J=8.0 Hz), 7.78 (2H, d, J=8.0 Hz), 7.68 (2H, d, J=8.0 Hz), 7.46 (2H, d, J=8.0 Hz), 7.36-7.30 (2H, m), 6.91 (2H, d, J=8.0 Hz), 6.79 (2H, d, J=8.0 Hz), 4.02 (2H, t, J=8.0 Hz), 3.82 (3H, s), 3.73 (3H, s), 3.31-3.26 (1H, m), 3.06 (1H, t, J=8.0 Hz), 2.96-2.89 (1H, m); MS (ES) [M+H]⁺597.2.

Example 2 Biological Effects of Representative Compounds

Cell Proliferation Assay

The cell proliferation was measured using the WST-1 proliferation assay kit. Briefly, an amount of 5-6×10³ cells per well were seeded in 96-well plates with a total volume of 100 μL. After culturing overnight, cells were treated with varying concentrations of compounds for 24 h at 37° C. with 5% CO₂. Then, 10 μL of WST-1 reagents were added to each well and the plate was incubated for another 2 h. The absorbance of each well was measured on a microplate reader at a test wavelength 460 nm. The inhibitory rate was calculated with the following equation: inhibition rate=100%×(OD control well−OD treated well)/(OD control well−OD blank well). Then inhibition curves were fit using GraphPad Prism 5 software and IC₅₀ (defined as the drug concentration that required for inhibiting growth by 50% relative to controls) was calculated.

Cell Cycle Analysis

Cells were treated with or without compounds at 37° C. with 5% CO₂. After incubation for 24 h, cells were collected by trypsinization and fixed with cold 95% ethanol over 30 min at 4° C. Subsequently, the cell suspension was centrifuged at 1000 rmp/5 min, and washed with PBS one time. The cell pellets were resuspended in 0.4 mL PBS and treated with RNAase A (0.1 mg/mL) at 37° C. for 30 min. Then, propidium iodine (50 μg/mL, PI) was added and the cells were stained for 30 min at 37° C. Analysis of cellular DNA content was performed by flow cytometry.

Migration Assay

The effect of compounds on inhibiting migration was evaluated using wound healing assay. Briefly, cells were seeded in a six well-plate, and a wound was generated by scratching the cell monolayer with a 200 μL pipette tip. Then, cells were continued to be cultured in the presence or absence of compounds, and the photographic recording was performed at 0 h, 24 h, and 48 h respectively. The number of the migrated cells was calculated with ImageJ software.

Effect of Compounds on Cytokine Expression

The lymph nodes and a spleen from mouse were collected, and then the immune cells were induced to differentiate towards Th1 cells in presence of α-CD3, α-CD28, IL-12, and IL-2. After obtaining Th1 cells, the cells were amplified and then the cells were treated with drugs. The expression level of the cytokine was analyzed using flow cytometry.

Antitumor Effect of Compounds on Azoxymethane (AOM)-Induced Mouse Colon Cancer Model

To induce colon cancer in situ, mice (four month old) were randomly divided into three groups: (1) AOM control group; (2) Compound 53 group, (3) CsA group, and injected with AOM subcutaneously (10 mg/kg body weight) once a week for 4 weeks. Then, Compound 53 and CsA group were treated with Compound 53 and CsA respectively for 8 weeks, and the control group was treated with 0.9% NaCl solution. Then, mice were killed and the colon was isolated. The number of the tumors formed was analyzed. Representative results are shown in FIGS. 14A and 14B, demonstrating that Compound 53, an exemplary CRAC inhibitor, demonstrated activity in this in vivo model by reducing the number of tumors formed compared to the control group.

While illustrative embodiments have been illustrated and described, it will be appreciated that various changes can be made therein without departing from the spirit and scope of the invention. 

1. A method of treatment of a disease, disorder, or condition treatable by inhibiting CRAC channel in a subject, comprising administering to a subject in need thereof an amount of a CRAC channel inhibitor effective to inhibit CRAC channel, wherein the CRAC channel inhibitor is a compound of Formula I:

or a pharmaceutically acceptable salt, solvate, or a hydrate thereof, wherein X is an optionally substituted C6-C10 aryl or an optionally substituted C5-C10 heteroaryl; Y is an optionally substituted C1-C8 alkyl, an optionally substituted C6-C10 aryl-C1-C8 alkyl, an optionally substituted C5-C10 heteroaryl-C1-C8 alkyl, an optionally substituted C3-C10 heteroalkyl, an optionally substituted C3-C6 heterocyclyl, an optionally substituted C6-C10 aryl, or an optionally substituted C5-C10 heteroaryl; and Z is an optionally substituted C6-C10 aryl or an optionally substituted C5-C10 heteroaryl.
 2. The method of claim 1, wherein X is an optionally substituted phenyl.
 3. The method of claim 1, wherein X is a phenyl substituted with one, two, or three groups selected from C1-C6 alkyl, carboxyl, alkoxycarbonyl, and amido group.
 4. The method of claim 1, wherein the compound has the structure of Formula II:

wherein R¹ is H, an optionally substituted C1-C6 alkyl, COOH, COOR², CONH₂, or CONHR²; R² is an optionally substituted C1-C6 alkyl; Y is an optionally substituted C1-C8 alkyl, an optionally substituted C6-C10 aryl-C1-C8 alkyl, or an optionally substituted C5-C10 heteroaryl-C1-C8 alkyl; and Z is an optionally substituted C6-C10 aryl or an optionally substituted C5-C10 heteroaryl.
 5. The method of claim 1, wherein Y is an optionally substituted phenethyl.
 6. The method of claim 1, wherein the compound has the structure of Formula III:

wherein R1 is H, COOH, COOR², or CONHR²; R² is an optionally substituted C1-C6 alkyl; R⁴ is H or an optionally substituted C1-C6 alkyl; R⁵ is H or an optionally substituted C1-C6 alkyl; and Z is an optionally substituted C6-C10 aryl or an optionally substituted C5-C10 heteroaryl.
 7. The method of claim 1, wherein Y is methyl, ethyl, propyl, n-butyl, tert-butyl, cyclopropyl, phenyl, benzyl, 4-methoxybenzyl, 3,4-dimethoxyphenyl, 4-sulfonamidophenethyl, or 5-methylbenzo[d][1,3]dioxolyl.
 8. The method of claim 1, wherein Z is phenyl, 4-halophenyl, 3-trifluoromethyl-phenyl, 2,5-dichlorophenyl, 3-chloro-4-methyl-phenyl, 2-methoxy-phenyl, 4-methoxycarbonyl-phenyl, benzo[d][1,3]dioxolyl, 3,5-dichlorophenyl, 3-methoxyphenyl, or 3-halophenyl.
 9. The method of claim 1, wherein the compound is:


10. The method of claim 1, wherein the condition is an immune system disease, a hyperplastic disease, or cancer.
 11. The method of claim 1, wherein the condition is colon cancer, breast cancer, leukemia, or glioma.
 12. The method of claim 1, wherein the condition is an organ or a tissue transplant rejection.
 13. A compound represented by Formula II:

or a pharmaceutically acceptable salt, solvate, or a hydrate thereof, wherein R¹ is selected from H, C1-C6 alkyl, COOH, COOR², or CONHR², and R² is an optionally substituted C1-C6 alkyl; Y is an optionally substituted C1-C8 alkyl, an optionally substituted C6-C10 aryl-C1-C8 alkyl, or an optionally substituted C5-C10 heteroaryl-C1-C8 alkyl; and Z is an optionally substituted C6-C10 aryl or an optionally substituted C5-C10 heteroaryl.
 14. The compound of claim 13, wherein Y is an optionally substituted phenethyl.
 15. The compound of claim 13, wherein Y is 4-sulfonamidophenethyl.
 16. The compound of claim 13, wherein the compound has the structure of Formula III:

wherein R¹ is H, an optionally substituted C1-C6 alkyl, COOH, COOR², CONH₂, or CONHR²; R² is an optionally substituted C1-C6 alkyl; R⁴ is H or an optionally substituted C1-C6 alkyl; R⁵ is H or an optionally substituted C1-C6 alkyl; and Z is an optionally substituted C6-C10 aryl or an optionally substituted C5-C10 heteroaryl.
 17. The compound of claim 13, wherein Y is methyl, ethyl, propyl, n-butyl, tert-butyl, cyclopropyl, phenyl, benzyl, 4-methoxybenzyl, 3,4-dimethoxyphenyl, 4-sulfonamidophenethyl, or 5-methylbenzo[d][1,3]dioxolyl.
 18. The compound of claim 13, wherein Z is phenyl, 4-halophenyl, 3-trifluoromethyl-phenyl, 2,5-dichlorophenyl, 3-chloro-4-methyl-phenyl, 2-methoxy-phenyl, 4-methoxycarbonyl-phenyl, benzo[d][1,3]dioxolyl, 3,5-dichlorophenyl, 3-methoxyphenyl, or 3-halophenyl.
 19. The compound of claim 13, wherein the compound is:


20. A pharmaceutical composition comprising the compound of claim 13 and a pharmaceutically acceptable carrier. 